Newly Described Myositis Autoantibodies: HMGCR, NT5C1A, SAE, PUF60

Zoe Betteridge; Neil J. McHugh

doi:10.1007/978-3-030-15820-0_22

Newly Described Myositis Autoantibodies: HMGCR, NT5C1A, SAE, PUF60

Zoe Betteridge
, Neil J. McHugh

Research output: Chapter or section in a book/report/conference proceeding › Book chapter

Abstract

Myositis autoantibodies can help subset patients into more homologous groups, aiding in diagnosis and helping to predict potential disease complications. In recent years, a number of novel myositis autoantibodies including anti-HMGCR, anti-SAE, anti-CN1A and anti-PUF60 have been identified and characterised, with the majority of myositis patients now having a detectable autoantibody. Preliminary studies have also led to the discovery of a number of emerging myositis autoantibodies including anti-SMN, anti-cortactin, anti-NPC and anti-FHL1, which when fully characterised may provide additional insight into disease pathogenesis as well as providing additional subsets in the serological classification of myositis. This chapter describes the prevalence and clinical associations of these new and emerging biomarkers.

Original language	English
Title of host publication	Managing Myositis
Subtitle of host publication	A Practical Guide
Editors	R. Aggarwal, C. Oddis
Place of Publication	Cham, Switzerland
Publisher	Springer International Publishing
Pages	199-207
Number of pages	9
ISBN (Electronic)	9783030158200
ISBN (Print)	9783030158194
DOIs	https://doi.org/10.1007/978-3-030-15820-0_22
Publication status	Published - 15 Dec 2019

Bibliographical note

Publisher Copyright:
© Springer Nature Switzerland AG 2020.

Keywords

Anti-3-hydoxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR)
Anti-cytosolic 5′-nucleotidase 1A (anti-CN1A)
Anti-poly(u)-binding-splicing factor (anti-PUF60)
Anti-small ubiquitin-like modifier (SUMO) activating enzyme (anti-SAE)
Myositis autoantibodies

ASJC Scopus subject areas

General Medicine
General Neuroscience

Access to Document

10.1007/978-3-030-15820-0_22

Cite this

@inbook{1b4393359314432889804361a4a019e8,

title = "Newly Described Myositis Autoantibodies: HMGCR, NT5C1A, SAE, PUF60",

abstract = "Myositis autoantibodies can help subset patients into more homologous groups, aiding in diagnosis and helping to predict potential disease complications. In recent years, a number of novel myositis autoantibodies including anti-HMGCR, anti-SAE, anti-CN1A and anti-PUF60 have been identified and characterised, with the majority of myositis patients now having a detectable autoantibody. Preliminary studies have also led to the discovery of a number of emerging myositis autoantibodies including anti-SMN, anti-cortactin, anti-NPC and anti-FHL1, which when fully characterised may provide additional insight into disease pathogenesis as well as providing additional subsets in the serological classification of myositis. This chapter describes the prevalence and clinical associations of these new and emerging biomarkers.",

keywords = "Anti-3-hydoxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR), Anti-cytosolic 5′-nucleotidase 1A (anti-CN1A), Anti-poly(u)-binding-splicing factor (anti-PUF60), Anti-small ubiquitin-like modifier (SUMO) activating enzyme (anti-SAE), Myositis autoantibodies",

author = "Zoe Betteridge and McHugh, \{Neil J.\}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2020.",

year = "2019",

month = dec,

day = "15",

doi = "10.1007/978-3-030-15820-0\_22",

language = "English",

isbn = "9783030158194",

pages = "199--207",

editor = "R. Aggarwal and C. Oddis",

booktitle = "Managing Myositis",

publisher = "Springer International Publishing",

address = "Switzerland",

}

TY - CHAP

T1 - Newly Described Myositis Autoantibodies

T2 - HMGCR, NT5C1A, SAE, PUF60

AU - Betteridge, Zoe

AU - McHugh, Neil J.

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2020.

PY - 2019/12/15

Y1 - 2019/12/15

N2 - Myositis autoantibodies can help subset patients into more homologous groups, aiding in diagnosis and helping to predict potential disease complications. In recent years, a number of novel myositis autoantibodies including anti-HMGCR, anti-SAE, anti-CN1A and anti-PUF60 have been identified and characterised, with the majority of myositis patients now having a detectable autoantibody. Preliminary studies have also led to the discovery of a number of emerging myositis autoantibodies including anti-SMN, anti-cortactin, anti-NPC and anti-FHL1, which when fully characterised may provide additional insight into disease pathogenesis as well as providing additional subsets in the serological classification of myositis. This chapter describes the prevalence and clinical associations of these new and emerging biomarkers.

AB - Myositis autoantibodies can help subset patients into more homologous groups, aiding in diagnosis and helping to predict potential disease complications. In recent years, a number of novel myositis autoantibodies including anti-HMGCR, anti-SAE, anti-CN1A and anti-PUF60 have been identified and characterised, with the majority of myositis patients now having a detectable autoantibody. Preliminary studies have also led to the discovery of a number of emerging myositis autoantibodies including anti-SMN, anti-cortactin, anti-NPC and anti-FHL1, which when fully characterised may provide additional insight into disease pathogenesis as well as providing additional subsets in the serological classification of myositis. This chapter describes the prevalence and clinical associations of these new and emerging biomarkers.

KW - Anti-3-hydoxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR)

KW - Anti-cytosolic 5′-nucleotidase 1A (anti-CN1A)

KW - Anti-poly(u)-binding-splicing factor (anti-PUF60)

KW - Anti-small ubiquitin-like modifier (SUMO) activating enzyme (anti-SAE)

KW - Myositis autoantibodies

UR - https://www.scopus.com/pages/publications/105012004271

U2 - 10.1007/978-3-030-15820-0_22

DO - 10.1007/978-3-030-15820-0_22

M3 - Book chapter

AN - SCOPUS:105012004271

SN - 9783030158194

SP - 199

EP - 207

BT - Managing Myositis

A2 - Aggarwal, R.

A2 - Oddis, C.

PB - Springer International Publishing

CY - Cham, Switzerland

ER -

Newly Described Myositis Autoantibodies: HMGCR, NT5C1A, SAE, PUF60

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this